Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387803 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation
A Phase 2 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 581
- Enrollment target
NCT00387803 is a Phase 2 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 581 participants.
The verdict
NCT00387803, a Phase 2 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 581 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.
Interventions
- DEVICE Cardiac Resynchronization Therapy with Defibrillation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 1998-02 |
| Est. Completion | 2001-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387803
The ClinicalTrials.gov registry entry for NCT00387803 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 581 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cardiac Resynchronization Therapy with Defibrillation is the first listed.
NCT00387803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387803 about?
NCT00387803 is a clinical study titled "Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation". The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.
What is the current status of trial NCT00387803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 581 participants. The study started on 1998-02. Estimated completion is 2001-08.
What interventions are being tested in trial NCT00387803?
The interventions under investigation include: Cardiac Resynchronization Therapy with Defibrillation (DEVICE).
Who is sponsoring clinical trial NCT00387803?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.